Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.
Faculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France.
Angiogenesis. 2024 May;27(2):211-227. doi: 10.1007/s10456-023-09902-8. Epub 2024 Jan 31.
Heterozygous activin receptor-like kinase 1 (ALK1) mutations are associated with two vascular diseases: hereditary hemorrhagic telangiectasia (HHT) and more rarely pulmonary arterial hypertension (PAH). Here, we aimed to understand the impact of ALK1 mutations on BMP9 and BMP10 transcriptomic responses in endothelial cells. Endothelial colony-forming cells (ECFCs) and microvascular endothelial cells (HMVECs) carrying loss of function ALK1 mutations were isolated from newborn HHT and adult PAH donors, respectively. RNA-sequencing was performed on each type of cells compared to controls following an 18 h stimulation with BMP9 or BMP10. In control ECFCs, BMP9 and BMP10 stimulations induced similar transcriptomic responses with around 800 differentially expressed genes (DEGs). ALK1-mutated ECFCs unexpectedly revealed highly similar transcriptomic profiles to controls, both at the baseline and upon stimulation, and normal activation of Smad1/5 that could not be explained by a compensation in cell-surface ALK1 level. Conversely, PAH HMVECs revealed strong transcriptional dysregulations compared to controls with > 1200 DEGs at the baseline. Consequently, because our study involved two variables, ALK1 genotype and BMP stimulation, we performed two-factor differential expression analysis and identified 44 BMP9-dysregulated genes in mutated HMVECs, but none in ECFCs. Yet, the impaired regulation of at least one hit, namely lunatic fringe (LFNG), was validated by RT-qPCR in three different ALK1-mutated endothelial models. In conclusion, ALK1 heterozygosity only modified the BMP9/BMP10 regulation of few genes, including LFNG involved in NOTCH signaling. Future studies will uncover whether dysregulations in such hits are enough to promote HHT/PAH pathogenesis, making them potential therapeutic targets, or if second hits are necessary.
杂合性激活素受体样激酶 1 (ALK1) 突变与两种血管疾病有关:遗传性出血性毛细血管扩张症 (HHT) 和更罕见的肺动脉高压 (PAH)。在这里,我们旨在了解 ALK1 突变对内皮细胞中 BMP9 和 BMP10 转录组反应的影响。我们从新生儿 HHT 和成年 PAH 供体中分别分离出携带功能丧失性 ALK1 突变的内皮细胞集落形成细胞 (ECFCs) 和微血管内皮细胞 (HMVECs)。对每种类型的细胞进行 RNA 测序,与对照相比,每种细胞在接受 BMP9 或 BMP10 刺激 18 小时后进行比较。在对照 ECFCs 中,BMP9 和 BMP10 刺激诱导了大约 800 个差异表达基因 (DEGs) 的相似转录组反应。令人意外的是,ALK1 突变的 ECFCs 无论是在基线水平还是在刺激后,其转录组谱与对照非常相似,而且 Smad1/5 的激活也无法用细胞表面 ALK1 水平的代偿来解释。相反,与对照相比,PAH HMVECs 显示出强烈的转录失调,基线时就有超过 1200 个 DEGs。因此,由于我们的研究涉及两个变量,即 ALK1 基因型和 BMP 刺激,我们进行了两因素差异表达分析,在突变的 HMVECs 中发现了 44 个 BMP9 失调基因,但在 ECFCs 中没有发现。然而,至少一个命中物,即疯狂的 fringe (LFNG) 的调节受损,在三个不同的 ALK1 突变的内皮模型中通过 RT-qPCR 得到了验证。总之,ALK1 杂合性仅修饰了 BMP9/BMP10 对少数基因的调节,包括参与 NOTCH 信号通路的 LFNG。未来的研究将揭示这些命中物的失调是否足以促进 HHT/PAH 发病机制,使它们成为潜在的治疗靶点,或者是否需要第二个命中物。